Rosuvastatin and ellagic acid protect against isoproterenol-induced myocardial infarction in hyperlipidemic rats  by Elhemely, Mai A. et al.
w.sciencedirect.com
b e n i - s u e f u n i v e r s i t y j o u r n a l o f b a s i c a n d a p p l i e d s c i e n c e s 3 ( 2 0 1 4 ) 2 3 9e2 4 6HOSTED BY Available online at wwScienceDirect
journal homepage: www.elsevier .com/locate/b jbasFull Length ArticleRosuvastatin and ellagic acid protect against
isoproterenol-induced myocardial infarction in
hyperlipidemic ratsMai A. Elhemely a, Hany A. Omar a,b,*, Afaf A. Ain-Shoka c,
Hekma A. Abd El-Latif c,d, Amira M. Abo-youssef a, Gamal A. El Sherbiny e
a Department of Pharmacology and Toxicology, Faculty of Pharmacy, Beni-Suef University, Beni-Suef 62514, Egypt
b Sharjah Institute for Medical Research, Department of Pharmacology, College of Pharmacy, University of Sharjah,
Sharjah 27272, United Arab Emirates
c Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Egypt
d Department of Pharmacology and Toxicology, Faculty of Pharmacy, Umm Al-Qurah University, Saudi Arabia
e Department of Pharmacology and Toxicology, Faculty of Pharmacy, Kafr El-Sheikh University, Egypta r t i c l e i n f o
Article history:
Received 12 September 2014
Accepted 5 October 2014
Available online 8 December 2014
Keywords:
Myocardial infarction
Hyperlipidemia
Isoproterenol
Rosuvastatin
Ellagic acid* Corresponding author. Department of Pha
Egypt. Tel.: þ20 01000882828; fax: þ20 082 2
E-mail address: omar.22@buckeyemail.os
Peer review under the responsibility of Ben
http://dx.doi.org/10.1016/j.bjbas.2014.10.010
2314-8535/Copyright 2014, Beni-Suef Universa b s t r a c t
Hyperlipidemia (HL) with subsequent coronary atherosclerosis is the major trigger of
ischemia and hence, myocardial infarction (MI) occurs. The present study aimed to
elucidate the effects of pretreatment with rosuvastatin and ellagic acid, as well as their
combination on isoproterenol-induced MI in hyperlipidemic rats. Adult rats were fed with
a cholesterol-rich diet for seven weeks and received rosuvastatin (10 mg/kg) and/or ellagic
acid (30 mg/kg) by oral gavage daily starting from the fifth week then subcutaneously
injected with two doses 24-h apart of 100 mg/kg isoproterenol in the last two days. ECG
pattern was monitored and both cardiac biomarkers (cTnI, CK-MB, LDH and AST) and lipid
profile (TC, TG, HDL-c and LDL-c) were measured in serum. MDA and GSH levels were
quantified in cardiac homogenates and heart tissue damage was examined by histopa-
thology. Furthermore, the expression levels of iNOS, eNOS, Bax and Bcl-2 in heart samples
were assessed by western blotting. Three-week pretreatment with rosuvastatin and/or
ellagic acid markedly ameliorated HL- and isoproterenol-induced alterations in ECG, car-
diac markers, oxidation markers, lipid profile and heart architecture. Both drugs down-
regulated iNOS and upregulated eNOS, while only rosuvastatin and the combination
downregulated Bax. This study provides evidence that rosuvastatin and ellagic acid
possess cardioprotective effect on the hyperlipidemic-myocardial infarction rat model and
the combination does not offer extra protection than monotherapy.
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Myocardial infarction (MI) is an acute necrotic disorder of the
heart which is expected to be the main reason for mortality in
the world by the year 2020 (Patel et al., 2010). It results from
sudden blockage of one or more of the coronary arteries that
deprives a myocardial segment from blood supply. The most
common recognized scenario for MI is coronary atheroscle-
rosis that is strongly correlated to hyperlipidemia (HL), an
important risk factor for acute coronary syndromes. HL in-
creases myocardial infarct size in experimental ischemia/
reperfusion injury as a consequence of the exaggerated
stimulation of myocardial apoptosis, thrombosis and inflam-
matory events (Ferdinandy, 2003; Balakumar and Babbar,
2012; Ma et al., 2013).
Oxidative stress is an important pathogenic event in a va-
riety of cardiovascular diseases such as atherosclerosis, hy-
pertension, ischemic heart disease and heart failure (Dhalla
et al., 2000; Mehany et al., 2013). It occurs when excessive
generation of reactive oxygen species (ROS) cannot be
adequately neutralized by endogenous antioxidants leading
to cell membrane injury and cell death (Takimoto and Kass,
2007; Galaly et al., 2014). In addition, increased ROS produc-
tion lessens the bioavailability of the vasodilator nitric oxide
(NO) which significantly affects the heart at both physiological
and pathological levels (F€orstermann, 2010). Low level of NO
produced by endothelial nitric oxide synthase (eNOS) regu-
lates vascular tone and provides cardioprotection from
ischemic damage (Jones and Bolli, 2006). On the other hand,
large amounts of NO, mediated by inducible nitric oxide syn-
thase (iNOS), are cardiotoxic due to suppression of myocardial
contractility and further increase of ROS generation and car-
diomyocyte apoptosis (Haywood et al., 1996; Wollert and
Drexler, 2002).
The apoptosis process is programmed and regulated by
numerous proteins such as Bcl-2 and Bax. Bcl-2, an anti-
apoptotic protein, is expressed shortly after MI onset,
whereas Bax, a pro-apoptotic protein, is overexpressed at the
old stage of MI (Krijnen et al., 2002). The role of apoptosis in
triggering MI is ambiguous, however, the major effect of
apoptosis appears to be on late cardiomyocyte loss and ven-
tricular remodeling after MI (Abbate et al., 2008).
So, the optimal therapeutic strategies to protect the heart
against MI should involve antihyperlipidemic, antioxidant,
anti-apoptotic and/or eNOS-mediated NO producing drugs. In
the current study, we selected rosuvastatin and ellagic acid as
cardioprotective candidates.
Rosuvastatin, a lipid-lowering agent in clinical practice,
has an appreciable anti-atherogenic property which is due to
the improvement of endothelial dysfunction as well as its
anti-thrombotic, anti-inflammatory and antioxidant effects
(Qu et al., 2009; Rondi et al., 2014). Rosuvastatin has been re-
ported to prevent MI induced experimentally by occlusion of
left coronary artery in rats (Dourado et al., 2011). Ellagic acid is
a polyphenolic compound that is found in strawberries,
pomegranates and grapes (Mari Kannan and Darlin Quine,
2012). It possesses a number of biological activities such as
antioxidant, antihyperlipidemic, anti-inflammatory and hep-
atoprotective effects (Rogerio et al., 2008). Ellagic acid has beenrecognized to have a cardiprotective effect against experi-
mentally induced MI (Kannan and Quine, 2013).
Catecholamines have a key role in normal cardiac func-
tion. However, isoproterenol, a synthetic catecholamine, lib-
erates ROS and causes an infarct-like necrosis of the
myocardium resembling MI in humans at toxic doses (Nagoor
Meeran et al., 2012).
The current study was executed in an effort to explore
whether rosuvastatin or ellagic acid alone or in combination,
could achieve cardioprotection against isoproterenol-induced
MI in cholesterol-rich diet fed rats.2. Materials and methods
2.1. Animals
Male Wistar rats of 140e160 g weight were provided from the
animal house of Faculty of Pharmacy, Beni-Suef University.
They were housed in plastic cages and kept under suitable
laboratory conditions that meet the guidelines of the Ethics
Committee, Faculty of Pharmacy, Cairo University.
2.2. Drugs and chemicals
Cholesterol and isoproterenol hydrochloride were bought
from Lobachemie (India) and SigmaeAldrich (USA), respec-
tively. Rosuvastatin was obtained kindly from Apexpharma
(Egypt), whereas ellagic acid was purchased from Acros (USA).
Test agents were prepared in 1% Tween 80 so that each 100 g
animal body weight received 0.5 ml orally of the respective
preparation.
2.3. Induction of HL
Rats were fedwith a cholesterol-rich diet (1% cholesterol, 0.2%
cholic acid, 0.2% methyl thiouracil, 7% egg yolk, 4% beef
tallow, 1% sodium chloride, 45%wheat flour, 6.6%wheat bran,
35% corn starch) for seven weeks (Pengzhan et al., 2003).
2.4. Induction of MI
Two doses 24-h apart of 100 mg/kg isoproterenol, prepared in
saline, were injected subcutaneously in rats (Zaafan et al.,
2013). The injected area was massaged for 30 s after injection.
2.5. Experimental design
At random, rats were divided into five groups (n ¼ 8). Groups I
& II, normal and hyperlipidemic-myocardial infarction (HM)
control groups, respectively, received 1% Tween 80 (p.o.).
Group III received rosuvastatin (10 mg/kg; p.o.) (Zaitone and
Abo-Gresha, 2012), while group 1V received ellagic acid
(30 mg/kg; p.o.). The combination of rosuvastatin with ellagic
acid was received by group V.
Except group I that was fed with a standard pelleted rat
chow, all groups were fed with the cholesterol-rich diet for 7
weeks (thewhole experimental period) andwere injectedwith
isoproterenol (100 mg/kg; s.c.) once daily in the last 2 days of
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tered starting from the 5th week.
At the end of the experiment, the animals were fasted over-
night for 12 h but had free access to water ad libtium. In the
morning, the rats were anaesthetized with ketamine HCl and
xylazine (50mg/5mg/kg; i.p.) simultaneously for ECG recording
(Struck et al., 2011). Thereafter, blood samples were collected,
the animalswere sacrificed by decapitation and theheartswere
removed rapidly. The collected blood samples, heart homoge-
nates (25%w/v in ice-cold saline) and heart samples were used
for the assessment of the chosen parameters.
2.6. ECG monitoring
Four needle electrodes were inserted under the anesthetized
rat's limb skin for ECG recording at lead II. Alterations in ST
segment were determined.
2.7. Biochemical analyses
The enzyme linked immunoassay (ELISA) technique was per-
formed to measure the serum level of troponin-I (cTnI) using a
standard kit (Glory Science Co., Ltd, USA). The serumactivity of
creatine kinase MB (CK-MB), lactate dehydrogenase (LDH) and
aspartate aminotransferase (AST) was determined using Bio-
systems kits (Spain). The serum levels of total cholesterol (TC),
triglycerides (TG) and high density lipoprotein cholesterol
(HDL-c) were quantified using Spinreact kits (Spain). For
measuring low density lipoprotein cholesterol (LDL-c) level in
serum, Friedewald equation [LDL-c¼ TC (HDL-cþ TG/5)] was
employed (Friedewald et al., 1972).
In the cardiac homogenate, malondialdehyde (MDA), an
indicator of lipid peroxidation, and reduced glutathione (GSH)
were estimated as mentioned before (Sedlak and Lindsay,
1968; Ohkawa et al., 1979).
2.8. Western blotting for iNOS, eNOS, Bax and Bcl-2
To extract proteins from cardiomyocytes, about 300 mg of
heart tissue was added to 150 ml of RIPA lysis buffer (Sigma-
eAldrich) and thoroughly ultra-homogenized (Omar et al.,
2009). After brief centrifugation, equal amounts of totalFig. 1 e Lead II ECG configuration of normal rat (A), HM rat (B), ro
rat (D), and rosuvastatin plus ellagic acid-pretreated HM rat (E).proteins were separated on 10% SDS-polyacrylamide gel and
electrophoretically transferred to a nitrocellulose membrane.
The membrane was blocked with TBST (10 mM TriseHCl,
100 mM NaCl, and 0.1% Tween 20) containing 5% nonfat dry
milk and incubated with a specific primary antibody (1:1000
dilution in 5%nonfatmilk in TBST) overnight at 4 C for each of
iNOS, eNOS, Bax and Bcl-2 (Proteintech, USA). After three
washes with TBST, the membrane was probed with rabbit IgG-
horseradish peroxidase conjugated secondary antibody (R&D
Systems, USA) for 2 h at room temperature. The immunoblots
were visualized by enhanced chemiluminescence system. b-
actin was assessed as the internal control.2.9. Histopathological examination
Tissue samples were taken from rat hearts from different
groups. These samples were fixed in 10% formalin prepared in
saline for about 48 h. Tissues were embedded in paraffin,
sectioned at 5 mm by slidge microtome and stained with he-
matoxylin and eosin (H&E). Photomicrographs were obtained
after examining the sections under light microscope.2.10. Statistical analysis
Statistical analysis was carried out using GraphPad Prism
statistical software. Measurements were displayed as
mean ± SEM. Groups were compared by one-way ANOVA and
subsequent TukeyeKramer test. At p value <0.05, differences
were considered significant.3. Results
3.1. Effect of three-week administration of rosuvastatin
and/or ellagic acid on ECG pattern
As compared to normal group, a noticeable elevation in ST-
segments was observed in HM group. Such alterations were
reinstated to proximate normal in rats pretreated with rosu-
vastatin, ellagic acid or their combination when compared to
HM group (Fig. 1).suvastatin-pretreated HM rat (C), ellagic acid-pretreated HM
Table 1 e Effect of three-week administration of rosuvastatin and/or ellagic acid on serum cardiac markers.
Groups cTnI (ng/L) CK-MB (U/L) LDH (U/L) AST (U/L)
Normal control 53.6 ± 1.41 216.9 ± 8.39 1623 ± 104.1 26.5 ± 1.06
HM control 74.9 ± 2.29* 512.9 ± 19.73* 4707 ± 313.7* 55.0 ± 2.35*
Rosuvastatin 53.6 ± 2.06@ 341.3 ± 7.06@ 1897 ± 164.4@ 36.1 ± 2.30@
Ellagic acid 59.0 ± 1.15@ 225.6 ± 19.29@ 1849 ± 148.8@ 36.7 ± 2.69@
Rosuvastatin þ Ellagic acid 62.3 ± 1.04@ 220.4 ± 16.45@ 2195 ± 111.2@ 37.1 ± 3.04@
*p < 0.05 compared to normal group and @p < 0.05 compared to HM group.
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and/or ellagic acid on cardiac markers
The serum level of cTnI, CK-MB, LDH and AST elicited a sig-
nificant rise in HM group as compared to normal group.
Rosuvastatin pretreatment decreased cTnI, CK-MB and LDH
levels by 28.5%, 33.5% and 59.7%, respectively relative to HM
group. Prior administration of ellagic acid produced a more
potent suppressant effect on the serum activities of CK-MB,
LDH and AST by 56.0%, 60.7% and 34.2%, respectively as
compared to HM group. Combination of rosuvastatin with
ellagic acid didn't show any appreciable difference than the
individual treatments (Table 1).
3.3. Effect of three-week administration of rosuvastatin
and/or ellagic acid on cardiac oxidative stress markers
Compared with normal group, HM group had a significant
elevation in cardiac MDA content, whereas no difference was
detected with respect to the cardiac content of GSH. Pre-
treatment with rosuvastatin reduced MDA by 34.5% with a
parallel increase in GSH by 96.5% as compared to HM group,
while ellagic acid pretreatment resulted in a 33.3% decrease in
MDA coupled with 59.8% increase in GSH. Upon administra-
tion of rosuvastatin combined with ellagic acid, MDA was
decreased and GSH was increased by 32.5% and 99.8%, corre-
spondingly relative to HM group (Table 2).
3.4. Effect of three-week administration of rosuvastatin
and/or ellagic acid on lipid profile
In HM group, compared with normal group, the levels of TC,
TG and LDL-c were markedly increased and HDL-c level wasTable 2 e Effect of three-week administration of
rosuvastatin and/or ellagic acid on cardiac oxidative
stress markers.
Groups MDA
(nmol/g wet tissue)
GSH
(mg/g wet tissue)
Normal control 26.46 ± 1.062 121.7 ± 6.614
HM control 55.02 ± 2.353* 141.9 ± 4.886
Rosuvastatin 36.05 ± 2.304@ 278.9 ± 17.65*@
Ellagic acid 36.71 ± 2.692@ 226.7 ± 20.69*@
Rosuvastatin þ Ellagic
acid
37.11 ± 3.041@ 283.7 ± 25.00*@
*p < 0.05 compared to normal group and @p < 0.05 compared to HM
group.markedly decreased. The lipid lowering capacity of ellagic
acid was the same as rosuvastatin. Regarding HDL-c level,
rosuvastatin and ellagic acid significantly elevated it by
102.5% and 284.2%, respectively as compared to HM group
(Table 3). But as a whole, there was no remarkable difference
in the lipid lowering activity upon administration of rosu-
vastatin, ellagic acid or combination of rosuvastatin with
ellagic acid.
3.5. Effect of three-week administration of rosuvastatin
and/or ellagic acid on iNOS, eNOS, Bax and Bcl-2 protein
expression in cardiomyocytes
In comparison with normal group, HM group revealed a sig-
nificant increase in the expression level of iNOSwith a parallel
decrease in eNOS level and provoked apoptosis as indicated
from higher level of Bax expression. There was no significant
difference among all groups regarding Bcl-2 protein level.
Pretreatment with rosuvastatin, ellagic acid or their combi-
nation markedly decreased the expression level of iNOS and
raised eNOS expression level as compared to HM group.
Regarding Bax, rosuvastatin and the combination effectively
downregulated its expression. Conversely, ellagic acid pre-
treatment resulted in no notable difference in Bax expression,
in comparison to HM group (Fig. 2).
3.6. Effect of three-week administration of rosuvastatin
and/or ellagic acid on myocardial architecture
On histopathological examination, HM group elicited necrotic
changes; nuclear pyknosis, karyorrhexis, karyolysis and
cytoplasmic eosinophilia. A massive granulation tissue was
formed inHMgroup to replace the infarcted one. Pretreatment
with either rosuvastatin or ellagic acid resulted in mild ne-
crosis, very mild granulation tissue and a marked decrease in
inflammatory cells infiltration. Heart of HM rat pretreated
with rosuvastatin plus ellagic acid exhibited approximately
normal architecture (Fig. 3).4. Discussion
Despite the fact that coronary heart disease is a complicated
disorder associated with hypertension, hyperlipidemia, dia-
betes and heart failure, most experimental studies of car-
dioprotection depend on induction of heart injury in absence
of other related diseases. Thus, we employed a combined
hyperlipidemic-myocardial infarction (HM) rat model that is
relevant to the clinical case of MI in humans. The current
Table 3 e Effect of three-week administration of rosuvastatin and/or ellagic acid on serum lipid profile.
Groups TC (mg/dl) TG (mg/dl) HDL-c (mg/dl) LDL-c (mg/dl)
Normal control 65.7 ± 2.24 26.3 ± 2.04 29.26 ± 0.98 28.25 ± 2.51
HM control 371.8 ± 23.13* 58.3 ± 2.03* 15.38 ± 0.56* 219.9 ± 12.17*
Rosuvastatin 135.5 ± 8.627@ 12.8 ± 0.52*@ 31.18 ± 1.93@ 125.6 ± 9.07*@
Ellagic acid 225.5 ± 18.37*@ 14.0 ± 0.93*@ 59.09 ± 3.89*@# 96.46 ± 4.53*@
Rosuvastatin þ Ellagic acid 150.2 ± 10.39*@ 9.5 ± 0.79*@ 33.87 ± 1.104@ 87.71 ± 5.61*@#
*p < 0.05 compared to normal control group, @p < 0.05 compared to HM control group and #p < 0.05 compared to rosuvastatin-pretreated HM
group.
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is the first to examine the cardioprotective potential of
rosuvastatin, ellagic acid and, especially, their combination
on isoproterenol-intoxicated rats in the presence of HL.
Alterations of ECG pattern, especially ST-segment eleva-
tion, represent the standard measure used to precisely di-
agnose MI in humans and animals (Panda et al., 2014). In our
study, HM group demonstrated a significant ST-segment
elevation which could be due to the deleterious effects of
isoproterenol on cardiac cell membrane integrity with sub-
sequent reduced mechanical capacity of the ventricles
(Thippeswamy et al., 2009). Similar ECG changes were re-
ported in isoproterenol-infarcted (Zaafan et al., 2013) and
hypercholesterolemic isoproterenol-infarcted rats (Abo-
Gresha et al., 2014).
Auto-oxidation of high doses of isoproterenol causes
extreme generation of cytotoxic ROS and consequently
impairment of integrity and function of myocardial mem-
branes occurs (Rona, 1985; Garjani et al., 2011). We observed
an increase in myocardial content of MDA in HM group which
is in agreement with other studies (Evran et al., 2014). How-
ever, no change in cardiac GSH level was observed in HM
group, as compared to normal group.
Isoproterenol-induced myocardial necrosis was evidenced
by the significant leakage of cTnI, CK-MB, LDH and AST from
the ruptured myocardial membranes into serum. Such car-
diotoxic effect of isoproterenol was confirmed by the histo-
pathological changes observed in HM group. These findings
are consistent with previous reports (Abo-Gresha et al., 2014).
In accordance with previous studies (Sherief et al., 2008;
Kannan and Quine, 2011), our findings have demonstratedFig. 2 eWestern blots showing the effect of rosuvastatin
and/or ellagic acid on the expression of iNOS, eNOS, Bax
and Bcl-2 in heart tissues subjected to hyperlipidemia and
isoproterenol-induced myocardial infarction (N, normal
control; HM, hyperlipidemic-myocardial infarction control;
Ros, rosuvastatin; EA, ellagic acid; Ros þ EA, combination
of rosuvastatin and ellagic acid).that pretreatment of HM rats with rosuvastatin, ellagic acid
and their combination successfully prevented the patholog-
ical ST-segment elevation and significantly lowered the
leakage of the cardiac biomarkers. Such observations could
be attributed to the potential role of rosuvastatin and ellagic
acid in protecting the myocardial membranes and in allevi-
ating the extent of myocardial damage. Owing to their
known antioxidant nature, rosuvastatin and ellagic acid as
well as their combination markedly reduced lipid peroxida-
tion as observed from decreasing MDA and replenishing GSH
levels in cardiomyocytes. In addition, the histopathological
changes of pretreated groups showed retardation of inflam-
mation and myonecrosis which could be attributed also to
the antioxidant and anti-inflammatory properties of rosu-
vastatin and ellagic acid (Kannan and Quine, 2011; Dube,
2014).
Both feeding with cholesterol-rich diet and injection of
isoproterenol led to extensive alteration of lipid profile in HM
group. This is in agreement with previous investigations
(NagoorMeeran et al., 2012; Abo-Gresha et al., 2014; Mahmoud
et al., 2014). The observed increase in TC, TG and LDL-c levels
in blood could initiate atherosclerosis with subsequent
ischemic heart disease (Ferdinandy et al., 2007). Pretreatment
with rosuvastatin, ellagic acid and their combination led to a
significant improvement in the lipid profile. Similarly to
rosuvastatin, ellagic acid's hypocholesterolemic effect is
mainly mediated via HMG-CoA reductase inhibition (Cheng-
Lai, 2002; Kannan and Quine, 2013).
Altered cardiac function and endothelial dysfunction were
reflected in HM group by the high iNOS and the low eNOS
expression levels. These results could be attributed to both the
detrimental toxic effects of isoproterenol on cardiomyocytes
and HL-induced myocardial oxidative stress (Cai and
Harrison, 2000; Li et al., 2006; Ribeiro et al., 2009). The obser-
vations that rosuvastatin downregulated iNOS and upregu-
lated eNOS were established previously in ischemic/
reperfused rats (Di Napoli et al., 2005). To the best of our
knowledge, the current study is the first one to demonstrate
the effect of ellagic acid on iNOS and eNOS in vivo. Interest-
ingly, pretreatment with ellagic acid downregulated iNOS and
upregulated eNOS and subsequently, an improvement of the
endothelial function and the coronary blood flow could be
expected.
Apoptosisplaysa role in the tissuedamageprocess following
MI and it was obvious in HM group from Bax overexpression in
cardiomyocytes. The induced apoptosis could be due to
isoproterenol-induced b-adrenergic stimulation and to some
extent due to HL. It was reported that ROS, generated from
Fig. 3 e Photomicrographs of cardiac sections from: (A) Normal control rat showing normal histologic pattern (H&E-x100), (B)
HM control rat showing necrotic changes and proliferated granulation tissue (arrow) (H&E-x200), (C) Rosuvastatin-
pretreated HM rat showing mild necrosis and very mild infiltration of leucocytes (H&E-x400), (D) Ellagic acid-pretreated HM
rat showingmild necrosis, very mild granulation tissue (arrow) (H&E-x200), and (E) Rosuvastatin plus ellagic acid-pretreated
HM rat showing no infarction and restoring the normal heart architecture (H&E-x200).
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central role in the regulationofmyocyteapoptosisvia activation
of the mitochondrial death pathway (Remondino et al., 2003).
HL-aggravated apoptosis could be due to lipid peroxidation and
inflammation (Wang et al., 2002). Here, rosuvastatin reduced
cardiomyocyte apoptosis by Bax downregulation andmild Bcl-2
upregulation. On the other hand, pretreatmentwith ellagic acid
was unable to significantly protect the cardiomyocytes from
apoptosis which contrasts with a report of anti-apoptotic effect
of ellagic acid on rats with MI (Mari Kannan and Darlin Quine,
2012). In such report, ellagic acid was administered in smaller
doses (7.5& 15 mg/kg/day) for a shorter period (10 days), which
could account for the disagreementwith our study. In addition,
the Bax discrepancy could be explained based on the reported
apoptosis-inducing activity of ellagic acid on cancer (Han et al.,
2006; Umesalma et al., 2014).
In conclusion, the collective antioxidant, lipid-lowering,
anti-inflammatory, iNOS downregulating and eNOS upregu-
lating properties of rosuvastatin and ellagic acid, and the anti-
apoptotic effect of rosuvastatin enabled them to protect rat
hearts from myocardial infarction in presence of hyperlipid-
emia. Unexpectedly, the combination did not show any
additional effect over the individual drugs.
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